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Controlled release of small interfering RNA
targeting midkine attenuates intimal hyperplasia in
vein grafts
Hiroshi Banno, MD,a,b Yoshifumi Takei, PhD,a Takashi Muramatsu, PhD,c Kimihiro Komori, MD,
PhD,b and Kenji Kadomatsu, MD, PhD,a,d Nagoya, and Aichi, Japan
Objective: Intimal hyperplasia is a major obstacle to patency after vein grafting. Despite of a diverse array of trials to
prevent it, a satisfactory therapeutic strategy for clinical use has not been established. However, sufficient inhibition of
early stages of intimal hyperplasia may prevent this long-term progressive disease. Midkine (MK) is a heparin-binding
growth factor that was originally discovered as the product of a retinoic acid-responsive gene. We previously demon-
strated that MK-deficient mice exhibit a striking reduction of neointima formation in a restenosis model, which is
reversed on systemic MK administration. In this study, we evaluated a strategy of using small interfering RNA (siRNA)
targeting MK as a therapy for vein graft failure.
Methods: We first made a highly effective siRNA to rabbit MK. Jugular vein-to-carotid artery interposition vein grafts,
which are applied to a low flow condition, were made in Japanese white rabbits. Small interfering RNA mixed with
atelocollagen was administrated to the external wall of grafted veins. Cy3-conjugated stabilized siRNA was used to
confirm its stability and successful transfer into the vein graft wall. Neointimal hyperplasia was evaluated 4 weeks after the
operation. The proliferation index and leukocyte infiltration were determined.
Results:MK expression was induced and reached the maximum level 7 days after operation. Fluorescence of Cy3-labeled
siRNA could be detected in the graft wall even 7 days after operation. Knockdown of the gradually increasing expression
was achieved by perivascular application of siRNA using atelocollagen. The intima-media ratio and the intima thickness
at 28 days after grafting were both reduced >90% by this treatment compared with controls. This phenomenon was
preceded by significant reductions of inflammatory cell recruitment to the vessel walls and subsequent cell proliferation
in MK siRNA-treated grafts.
Conclusions: These results suggest that midkine is a candidate molecular target for preventing vein graft failure.
Furthermore, for clinical applications of siRNA, a single intraoperative atelocollagen-based nonviral delivery method
could be a reliable approach to achieve maximal function of siRNA in vivo. This strategy may be a useful and practical
form of gene therapy against human vein graft failure. ( J Vasc Surg 2006;44:633-41.)
Clinical Relevance: Intimal hyperplasia is a major obstacle to patency after vein grafting. Despite a diverse array of trials
to prevent it, a satisfactory therapeutic strategy for clinical use has not been established. However, sufficient inhibition of
early stages of intimal hyperplasia may prevent this long-term progressive disease. Here, we report almost complete
suppression of intimal hyperplasia. Knockdown of growth factor midkine expression was achieved by the perivascular
application of small interfering RNA (siRNA) using atelocollagen. Our data indicate that the combination of siRNA and
its controlled release could be a therapeutic strategy for vein graft failure and that midkine is a potent molecular target for
the prevention of intimal hyperplasia.An autologous vein is the most commonly used con-
duit for peripheral bypass grafting in the treatment of
ischemia resulting from occlusive vascular disease. How-
ever, the vein graft patency is limited by progressive intimal
hyperplasia and subsequent atherosclerosis, with patencies
of 80% for 1 year and 60% for 5 years.1,2 The patencies can
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Hemodynamic factors such as a low flow velocity and a low
shear stress result in intimal thickening.3-8 Considering the
high use of the procedure, approximately 100,000 lower
extremity bypasses are performed in the United States each
year,9 a means to solve the stenosis problem has been
awaited. In addition, coronary artery bypasses and percuta-
neous transluminal coronary angioplasty are also problem-
atic at similar frequencies.10,11
A diverse array of molecular targets for each step have
been postulated, including monocyte chemoattractant
protein-1, E2F, c-myc, matrix metalloproteinase, and
transforming growth factor , and many trials for the
prevention of stenosis have been performed.9,12-25 Never-
theless, a satisfactory strategy for clinical use has not been
established.9,12
Midkine (MK) is a heparin-binding growth factor that
was originally discovered as the product of a retinoic acid-
responsive gene.26,27 MK exhibits 50% sequence identity
with the pleiotrophin/heparin-binding growth-associated
molecule (PTN/HB-GAM).28-31 The three major biologic
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mation.30 MK supports neuronal cell survival and neurite
extension.32,33 The neuronal cytoprotective effect of MK
has been demonstrated in various in vivo models, including
retinal degeneration induced by constant light exposure,34
cerebral infarction,35 and ischemia-induced neuronal
death.36,37 In human carcinomas, MK expression is often
elevated and is associated with a poor prognosis. MK anti-
sense oligodeoxyribonucleotide (ODN) can suppress MK
expression and tumor formation.38 In addition, MK is
involved in inflammation, as revealed by studies involving
MK-deficient (Mdk/) mice. Ischemic reperfusion-in-
duced renal damage,39 cisplatin-induced renal damage,40
and rheumatoid arthritis41 are manifested to a lesser extent
inMdk/mice. MK antisenseODN can suppress ischemic
reperfusion-induced renal damage42 and cisplatin-induced re-
nal damage in Mdk/ mice.40
We previously reported that Mdk/ mice exhibit a
striking reduction of intimal hyperplasia in an arterial reste-
nosis model.43 MK expression is transiently increased, the
maximum level being reached at day 7, in a rat balloon
injury model, in which the intimal hyperplasia is completed
at about day 14.43 Supporting these data, MK antisense
oligodeoxyribonucleotide (ODN) suppresses MK induc-
tion and consequently intimal hyperplasia in a rabbit bal-
loon denudation model.44 However, the ODN suppressed
intimal hyperplasia by 40% compared with control treat-
ment.44 We speculated that this modest effect was attribut-
able to MK expression being gradually induced, whereas
the ODN was administered only once at the time of oper-
ation. Therefore, a means of longstanding, full knockdown
of MK appeared to be needed.
Here, we report that the combination of siRNA with
MK and its controlled release using atelocollagen led to
striking suppression of intimal hyperplasia in a vein graft
model. This study provides a strategy for sufficient preven-
tion of intimal hyperplasia.
MATERIALS AND METHODS
SiRNAs. Five siRNAs targeting rabbit MK and one
scrambled siRNA with the following sense and antisense
sequences were synthesized: #1 (bases 65-83), 5’-
CCAAAAAGAAAGACAAGGUdTdT-3’ (sense), 5’-
ACCUUGUCUUUCUUUUUGGdTdT-3’ (antisense);
#2 (bases 316-334), 5 CUGAAGAAGGCUCG-
GUACAdTdT-3’ (sense), 5’-UGUACCGAGCCUUCU-
UCAGdTdT-3’ (antisense); #3 (bases 383-401), 5’-
AGACCAAAGCCAAGGCCAAdTdT-3’ (sense), 5’-
UUGGCCUUGGCUUUGGUCUdTdT-3’ (antisense);
#4 (bases 404-420), 5’-CCAAGAAAGGGAAGG-
CAAAdTdT-3’ (sense), 5’-UUUGCCUUCCCUUUCU-
UGGdTdT-3’ (antisense); #5 (bases 410-428), 5’-
AAGGGAAGGCAAAGGACUAdTdT-3’ (sense), 5’-
UAGUCCUUUGCCUUCCCUUdTdT-3’(antisense);
and #2-SCR, 5 ’ -GGCGGCUCAUGAAC-
GAAUAdTdT-3’ (sense), 5’-UAUUCGUUCAU-
GAGCCGCCdTdT-3’ (antisense). All the siRNAs were
designed by B-Bridge International, Inc, Sunnyvale, Calif,and synthesized by Dharmacon, Inc, Lafaytte, Colo, using
2’27-bis (acetoxyethoxy)-methyl ether (ACE) protection
chemistry. We selected siRNA sequences as reported by
Elbashir et al.45 Each freeze-dried siRNA was reconstituted
in RNase-free water to prepare a 20 mol/L stock solu-
tion. For the in vivo study, we used stabilized siRNAs,
which were modified siRNAs with improved stability and
silencing longevity (siSTABLE, Dharmacon). We also used
Cy3-conjugated stabilized siRNAs to confirm their stability
and successful transfer into vein grafts.
Cell culture conditions and transfection of siRNAs
in vitro. RK13 cells (American Type Culture Collection,
Manassas, Va) derived from rabbit kidney were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) contain-
ing heat-inactivated fetal bovine serum at 37°C under a
humidified atmosphere of 5% carbon dioxide. Cells were
plated at a density of 1  105 cells/35 mm tissue culture
dish 20 hours before transfection, resulting in 30% to 50%
confluence on the day of transfection. In a separate tube, 5
L of each siRNA stock solution (20 mol/L) was diluted
with 95 L of Opti-MEM (Invitrogen, Carsbad, Calif),
and 3 L of Lipofectamine 2000 (Invitrogen) was diluted
with 97 L Opti-MEM. The diluted siRNAs and diluted
Lipofectamine 2000 were then combined, gently mixed,
and incubated for 20 minutes at room temperature. The
siRNA and Lipofectamine 2000mixture was added directly
to the cells in 0.8 mL of culture medium. The medium was
replaced with serum-free DMEM containing heparin (20
g/mL) 48 hours after transfection. After 24 hours of
incubation, the conditioned medium was collected for
Western blot analysis.
Vein graft model and in vivo transfection. Japanese
white rabbits (2.5 to 3 kg) were anesthetized by intramus-
cular administration of ketamine (35 mg/kg) and xylazine
(10 mg/kg). The no-touch technique was used to dissect
out a 25-mm segment of the right external jugular vein
through a midline vertical neck incision, and all branches
were carefully ligated with 8-0 polypropylene sutures and
divided. The animals were systemically heparinized (200
U/kg). The ipsilateral common carotid artery was clamped
distally and proximally, and a graft was anastomosed in an
end-to-end fashion into the divided artery with interrupted
8-0 polypropylene sutures.
Atelocollagen (Koken Co, Ltd, Tokyo, Japan) was used
for transfection in vivo. Atelocollagen is a highly purified
type 1 collagen derived from calf dermis by pepsin treat-
ment. Before the operation, siRNAs and atelocollagen
complexes were prepared as follows: 300 L of 3.5% atelo-
collagen and 300 L of a stabilized siRNA solution (20
mol/L) or saline alone were mixed and kept at 4°C before
use. Then the mixture was used to coat the external surface
of the vein graft. This complex formed a gel after appropri-
ate heat treatment with a hair dryer, which was used for
10 seconds and did not dry or injure the vein grafts. This
resulted in incubation of siRNAs around the graft for at
least 1 week. Before wound closure, the grafts were sub-
jected to low flow conditions as described previously.46 The
animal experiments in the present study were performed in
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tory Animal Research, Nagoya University Graduate School
of Medicine.
Western Blot analysis. A whole graft explanted on
the indicated day after operation was snap-frozen, ground
into powder, and then lysed in 1 mL of 10 mM Tris-HCl
(pH 7.4) containing 150 mmol/L sodium chloride, 1%
Triton X-100, and 1 mmol/L phenylmethylsulfonyl fluo-
ride. The supernatant of the lysate obtained on centrifuga-
tion was subjected to Western blot analysis as described
previously.47
Fluorescence microscopy. Cy3-conjugated stabilized
siRNAs were used to confirm their stability and successful
transfer into the vein graft wall. Grafts coated with atelo-
collagen with or without the siRNAs were harvested 1 week
after operation and immediately embedded in OCT com-
pound and frozen in liquid nitrogen. A cryostat was used to
cut 4-m-thick sections, which were then observed (MRC-
1024, Bio-Rad Laboratories).
Histopathology, immunostaining, and morphometry.
Vein grafts were fixed at 100 mm Hg for 20 minutes and
Fig 1. Increased midkine (MK) expression in a rabbit vein graft.
A, The time course of MK expression in the rabbit vein graft is
shown. Protein extracts of grafted veins at the indicated times after
operation were subjected to Western blot analysis for MK and
-actin. B, Immunostaining for MK 7 days after operation is
shown (upper left and right). A magnified photo of the upper left
panel is shown at upper right. The bottom panel shows a control
staining without the first antibody of an adjacent section. Bars, 100
m.immersed overnight in 4% paraformaldehyde, and thenfour evenly spaced segments (4 to 5 mm apart) of the
middle portion of each graft were embedded in paraffin.
Serial sections were stained with hematoxylin and eosin or
elastic Van Gieson stain, and were also stained for the
detection of proliferating cell nuclear antigen (PCNA,
1:100; Ki-67, 1:75; Dako, Glostrup, Denmark). Frozen
sections made after 7 days were used for the detection of
leukocytes (CD45, 1:100; Pharmingen, San Jose, Calif).
Controls for the immunostaining included incubation with
class-matched and species-matched immunoglobulins (Ig)
and omission of primary antibodies. For MK immunostain-
ing, we used chicken antihuman MK (IgY), which recog-
nizes rabbit MK, as the primary antibody and chicken IgY
as the control. Intimal hyperplasia was quantitated by using
imaging software (ImageJ, National Institutes of Health,
Bethesda, Md).
Intimal and medial cross-sectional areas were mea-
sured, and the neointimal thickness was measured at eight
randomly selected points for each section. The proliferation
index was determined by dividing the number of positively
stained nuclei by the total number of nuclei in the intima of
each section. The leukocyte count was determined as the
total number of CD45 cells in the graft wall of each
section. The intima-media ratio, intimal thickness, prolifer-
ation index, and cell counts were determined from these
data, and the averages for each vessel were calculated. Two
observers controlled the obtained values for randomly se-
lected multiple samples.
Statistical analysis. Stat View 5.0 (SAS Institute,
Cary, NC) software was used for statistical calculations.
Values are expressed as means SEM, and compared with
the double-placebo-treated control group by means of
analysis of variance involving the Bonferroni post hoc anal-
ysis. Comparisons between two groups were performed
with the unpaired t or Mann-Whitney U test. P  .05 was
considered statistically significant.
RESULTS
MK expression in a rabbit vein graft. A controlled
release of MK knockdown reagents applied from outside
into the vein wall was possible because the vein wall is
thinner and looser than that of the artery. In contrast to the
limited use of the mouse model because of high-level
techniques, rabbit vein graft models are commonly used
and we already had a complimentary DNA sequence of
rabbit MK. We therefore decided to use a rabbit vein graft
model in the present study.
A healthy ungrafted vein expresses tiny amounts of
MK. The interposition of a vein into an arterial vessel,
however, led to a significant increase in MK expression, the
maximum level being reached 7 days after operation. It
then decreased but persisted 4 weeks (Fig 1). At 7 days
after operation, strong MK expression was noted in intimal
and endothelial cells and moderate expression in medial
cells (Fig 1).
Effects of siRNAs onMK expression by RK13 cells.
SiRNA degrades RNA and thus inhibits expression of a
target molecule at the RNA level. The overall inhibition
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application of siRNA has become realistic with current
techniques; therefore, we used siRNA in this study. We
designed five rabbit MK siRNAs (Fig 2). MK siRNA #2
most strongly suppressed the secretion of MK by rabbit
kidney cell line RK13 (Fig 2). Densitometric analysis of a
Western blot revealed that it suppressed MK production to
Fig 2. Effects of small interfering RNAs (siRNAs) targ
A,The full-length rabbitMK complimentary DNA seque
five siRNAs examined in this study are indicated by
Lipofectamine 2000 alone (mock), or not treated (n	 3
relative densitometric intensities of Western blot bands o
in the graph (n 	 3). C, Stabilized siRNAs retained in
Western blot for MK is shown.9% of that in control cultures (Fig 2). Scrambled siRNA(MK siRNA #2-SCR) showed no effect (Fig 2). We also
confirmed that the stabilized siRNAs retained inhibitory
effects equal to those of the unmodified siRNAs (Fig 2).
Hereafter, we used the stabilized siRNAs for all animal
experiments.
Stability and successful transfer of siRNAs. We
used a vein graft model with poor runoff because this model
rabbit midkine (MK) on its expression in cultured cells.
nd design of siRNAs targeting rabbitMK are shown. The
B, RK13 cells were transfected with MK siRNAs or
s). A representative Western blot for MK is shown. The
were calculated and are presented as the average SEM
ry effects equal to those of the unmodified siRNAs. Aeting
nce a
bars.
dishe
f MK
hibitomimics the clinical situation in which vein grafting is per-
shown in the graph (n	3).
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After external jugular vein-carotid artery interposition,
three of four distal vessel branches were ligated, resulting in
an approximately 90% reduction in flow, from 30 to 3
mL/min, as measured by an ultrasonic flowmeter. The
consequent low blood flow in the grafted vein facilitates
intimal hyperplasia.29
To examine the localization and stability of a siRNA in
the vein graft wall, a Cy3-conjugated stabilized siRNA was
mixed with atelocollagen and then perivascularly applied to
the grafted vein. To achieve uniformity of treatment and
precise dosing, the concentration of atelocollagen rather
than the absolute amount of atelocollagen may be impor-
tant. We tested 0.5%, 0.75%, 1.0%, and 1.75% (final con-
centration) of atelocollagen. Atelocollagen at 0.5% to 1.0%
was barely solidified and thus not useful for our model.
Atelocollagen at 1.75% was easily solidified and uniformly
wrapped the vein graft. We also tested a hard sheet of
atelocollagen. Although this sheet absorbed siRNA, it did
not release siRNAwhen set around the vein graft of rabbits;
therefore, we used atelocollagen at the final concentration
of 1.75%.
As atelocollagen becomes solidified at normal body
temperature, Cy3-conjugated stabilized siRNAmixed with
atelocollagen remained at the application site after opera-
tion. Fig 3 shows that transfection involving atelocollagen
led to a good infiltration and stability of siRNA in the graft
wall for at least 7 days after operation. A graft with the
vehicle alone showed no fluorescence signal (Fig 3, bottom
on right), indicating that the pictures in Fig 3 do not show
autofluorescence.
Treatment of vein grafts with MK siRNAs. We
perivascularly applied MK siRNA mixed with atelocollagen
to a vein graft at operation. MK siRNA suppressed MK
expression to approximately 28% of the scrambled siRNA
level, as estimated 7 days after operation (Fig 3). However,
the suppression was not observed at 14 days after operation
(Fig 3).
The significant effect of MK siRNA on MK expression
in a grafted vein prompted us to evaluate its potential for
prevention of intimal hyperplasia. Treatment of grafts with
atelocollagen containing a MK siRNA led to significant
reductions in the intima-media ratio and intimal thickness
at 4 weeks (0.21  0.04 m and 17  3 m, respectively;
n 	 5; P  .05), compared with grafts that were untreated
(3.08  0.29 m and 204  31 m), treated with atelo-
collagen (3.16 0.67 m and 162 44 m), and treated
with atelocollagen containing scramble siRNA (2.96 
0.30 m and 170  11 m) (Fig 4).
Effects of MK siRNAs on cell proliferation and
leukocyte infiltration. Control vein grafts, which were
treated with scrambled siRNA, showed highly frequent cell
proliferation in the intimal lesion and less but significant
proliferation in the media and adventitia at 14 days after
operation (Fig 5, A and B). Vein grafts treated with MK
siRNAs showed a significant decrease in the number of
proliferating cells in the neointima of the vessel comparedFig 3. Controlled release of small interfering RNA (siRNA) into
the grafted vein wall.A, A poor run-off vein graft model with distal
branch ligation is depicted. The most inferior branch of the exter-
nal carotid artery serves as the only outflow for the low-flow graft.
CCA, common carotid artery; ECA, external carotid artery; ICA,
internal carotid artery; VG, vein graft. B, Successful transfer in vivo
was determined by fluorescent photomicrography of atelocollagen
with a Cy3-conjugated scrambled siRNA-treated graft 7 days after
operation. Low (upper left) and high (lower left)magnifications are
shown. The upper right panel shows an adjacent section stained
with hematoxylin and eosin. Note the absence of the Cy3 signal
(red color) in the graft treated with atelocollagen without siRNA
(lower right). The dotted line indicates the internal edge of the
vessel. A, atelocollagen; L, indicates lumen. C, The effect of
midkine (MK) siRNA on MK expression at 7 days after operation
was assessed by Western blot. Relative densitometric densities arewith grafts treated with scrambled siRNA (10.4% 1.8% vs
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1.2% for Ki-67, P  .001) (Fig 5). In contrast, an apparent
difference in cell proliferation between grafts treated with
MK siRNA and those treated with scrambled siRNA-
treated was not observed at 7 days after operation (data not
shown). Apoptosis in grafted veins was also examined but
was barely detectable, even in specimens in which MK
siRNA was administered (data not shown).
To identify an earlier event affected by MK siRNA
treatment, we examined the inflammatory response. Im-
munostaining for the CD45 antigen at 7 days after opera-
tion revealed extensive leukocyte infiltration in the control
graft walls (Fig 6). MK siRNA treatment significantly re-
duced the leukocyte count from15.0 2.7 per microscopic
field (200) in controls to 2.2 0.5 (n 	 5, P  .05).
DISCUSSION
Many trials that have been performed, including ge-
netic interventions to prevent vein graft failure, have taken
advantage of the fact that veins to be grafted can be
manipulated ex vivo. Antisense or decoy ODNs have been
transfected into a graft vein wall via liposomes or high
pressure, or both.12,17,19,21,48,49 However, a conceivablelimitation of this strategy is that a drug is administered only
once, and a major part of the applied drug does not remain
at the application site for very long. The second strategy is
ex vivo administration of adenovirus expressing antisense
DNAs.15,16,24,25 An alternative strategy is to wrap a grafted
vein with a Pluronic gel containing antisense ODNs or
aspirin.13,14,22,23
Considering the modest suppression of intimal hyper-
plasia on a one-shot application of the MK antisense ODN
at the initial stage,44 we attempted in this study to develop
a method to achieve long-standing sufficient suppression of
MK expression. We used atelocollagen to deliver a siRNA.
Atelocollagen is a liquid at 4°C, becomes solid at 37°C,
and has been used as a delivery system for expression
plasmids, antisense ODNs and siRNAs.38,50,51 The advan-
tage of the use of atelocollagen is that it becomes stabilized
and slowly releases nucleic acid reagents.51 It is of note that
the present combination of MK siRNA and atelocollagen
led to almost complete suppression of intimal hyperplasia
and the best results among those reported so far.
The present method has two excellent advantages.
First, the complicated transfection procedures reported in
Fig 4. Quantification of intimal hyperplasia. A,
Representative elastic Van Gieson-stained sections
from animals at 4 weeks after operation. Represen-
tative photos at low (above) and high (below) mag-
nifications are presented. Arrowheads indicate the
internal elastic lamina. Bars, 1 mm. B, The graph
shows the intima-media ratio (left) and intimal
thickness (right) (n 	 5 in each group, *P  .05 by
analysis of variance with the Bonferroni post hoc
analysis). SCR siRNA, scrambled small interfering
RNA; MK, midkine.previous studies are not needed. Second, the siRNA is
intima (n	5, *P  0.001). Bars, 200 m.
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suppression of the target gene. Drug delivery systems in-
volving liposomes or high pressure may only allow drugs to
remain for a few hours to a day at the application site. Thus,
such delivery systems may not provide a sufficient suppres-
sion effect of gene expression.
We observed that MK expression was suppressed for at
least 7 days in the present study. Although our method did
not allow sufficient suppression of MK expression at 14
days after operation, taking into account that neointima
formation becomes visible at 7 days and we observed strik-
ing suppression of it at 28 days, the early stage suppression
of MK expression is probably enough to reduce neointima
formation. We speculate that MK expressed in the early
stages initiates a chain reaction involving several molecules
inducing inflammation in the vessel wall, and that this chain
reaction is consequently critical in neointima formation. In
addition, although MK does not enhance proliferation of
vascular smooth muscle cells, it does enhance migration of
macrophages and vascular smooth muscle cells.43 Together
with unknown factor(s) secreted from vascular smooth
muscle cells, MK promotes vascular smooth muscle cell
migration.43 This activity may contribute to intimal thick-
ening. Although themolecular cascade afterMK remains to
be elucidated, our study has provided evidence that the
suppression of molecular events at the early stages is a good
strategy for the prevention of vascular stenosis.
We have obtained the following evidence:
1. MK is specifically induced in the intima during intimal
Fig 6. Leukocyte infiltration into a grafted vein 7 days after
operation. CD45-immunostained sections of grafts treated with
midkine (MK) short interfering RNA (siRNA) (left) and scram-
bled siRNA (SCR siRNA) (right) are shown. The bar graph shows
the numbers of CD45 cells in the graft walls (n	 5, *P 0.05).
Bars, 100 m.hyperplasia (present study).43Fig 5. Cell proliferation in a grafted vein 14 days after operation.
A, Proliferating cell nuclear antigen (PCNA)-immunostained sec-
tions of grafts treated with midkine (MK) small interfering RNA
(SCR siRNA) (upper panel) and scrambled siRNA (SCR siRNA)
(lower panel). High magnification views are shown on the right.
The bar graph shows the percentage of PCNA-positive cells in the
intima (n 	 5, *P  .01). B, Ki-67-immunostained sections of
grafts treated with MK siRNA (upper panel) and scrambled siRNA
(lower panel).High magnification views are shown on the right.
The bar graph shows the percentages of Ki-67-positive cells in the
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and exogenously administered MK restores it43
3. Suppression of MK expression leads to suppression of
intimal hyperplasia (present study).44 Overall, MK is a
potent molecular target for the prevention of vascular
restenosis.
MK was discovered as the product of a retinoic acid-
responsive gene and is implicated in inflammation.26,27,30
Evidence supporting the inflammation-promoting activity
of MK has accumulated through the use several systems,
such as a neutrophil migration assay, a reperfusion-induced
renal injury model, a cisplatin-induced renal injury model,
and a rheumatoid arthritis model.39-41,52 We previously
showed that neutrophil and macrophage infiltration into
vascular walls is strikingly suppressed in MK-deficient mice
in an arterial restenosis model compared with wild-type
mice.26 The present study demonstrated a close association
of MK knockdown and suppression of inflammatory cell
recruitment and thus strengthens the importance of MK in
the inflammation in this disease.
This study used a stabilized siRNA that was developed
to have extremely high stability in the blood and thus is
resistant to many nucleases. Because atelocollagen stabi-
lizes siRNA,38 it will be important in terms of the feasibility
of clinical application to determine whether a siRNA with a
natural backbone is also effective combined with atelocol-
lagen.
CONCLUSION
We demonstrated in this study that MK could be a
potent molecular target for the prevention of vein graft
failure. The combination of siRNA and its controlled re-
lease by means of atelocollagen or other polymers can be
used not only for perivascular application on vein grafting
but also for siRNA-eluting stents for a broader spectrum of
vascular restenosis including that after percutaneous trans-
luminal coronary angioplasty.11
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